SynthesisRheumatology international2025
The global prevalence of interstitial lung disease in patients with rheumatoid arthritis: a systematic review and meta-analysis.
Synthesis in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic methods of rheumatoid arthritis-associated interstitial lung disease: a systematic review.Rheumatology international · 2026Pooled it
- Prevalence of interstitial lung disease in patients with psoriatic arthritis: a systematic review and meta-analysis.Clinical rheumatology · 2026Pooled it
- Association of ICD-10-Coded Pneumonia Events with Interstitial Lung Disease Outcomes in Patients with Rheumatoid Arthritis: A Large Database Retrospective Cohort.Advances in respiratory medicine · 2026Article
- Interstitial Lung Disease in Rheumatoid Arthritis: Incidence and Outcomes in Western Australia.International journal of rheumatic diseases · 2026Article
- [Development and validation of a risk assessment model for interstitial lung disease in patients with rheumatoid arthritis].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Evolving landscape of imaging-based evaluation in systemic autoimmune rheumatic disease-associated interstitial lung disease: from visual assessment to quantitative artificial intelligence-assisted evaluation.Journal of rheumatic diseases · 2026Review
- Regulation of basal and tumour necrosis factor α-induced fibroblast gene expression by peptidylarginine deiminase 2.The Journal of physiology · 2026Article
- Incidence and spectrum of primary respiratory disease throughout the course of rheumatoid arthritis: implications of structured repeated evaluation for detection and risk-factor analysis.Arthritis research & therapy · 2026Article
- Radiological extent predicts prognosis and relapse after acute exacerbation of interstitial lung disease in patients with rheumatoid arthritis: KEIO-RA-cohort.Rheumatology international · 2025Article
- Ferroptosis: New Strategies for Clinical Treatment of Rheumatoid Arthritis.Journal of inflammation research · 2025Review
- Risk of Serious Adverse Events and Death With Low-Dose Methotrexate Versus Hydroxychloroquine in Adults Receiving Dialysis.Seminars in dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to review the literature and estimate the global pooled prevalence of interstitial lung disease among patients with rheumatoid arthritis (RA-ILD). The influence of risk factors like geography, socioeconomic status, smoking and DMARD use will be explored. A systematic review was performed according to the PRISMA and JBI guidelines. Studies published between January 1980 and February 2024 were sourced from 7 electronic databases and screened for eligibility. A random-effects meta-analysis model was used to produce pooled prevalences and the potential between-study heterogeneity was identified using sensitivity, subgroup, meta-regression and correlation analyses. 33 studies were included in this meta-analysis containing 14,281 RA patients. The global pooled prevalence of RA-ILD was 21.38% (CI: 0.1542-0.2886), with a high heterogeneity (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.